THERAPiN

Company Overview

Snapshot

Founded in September 2017, THERAPiN operates with 1–10 employees. The company has raised a total of $22 million across 2 funding rounds from 1 investor, reaching a Series A stage. THERAPiN is focused on the development and production of cannabis products for medical and cosmetic applications.

Business overview

THERAPiN is a Health Tech & Life Sciences company specializing in the Pharma & Medical Biotechnology sector, with a focus on Medical Cannabis. The company develops, cultivates, and manufactures raw materials and premium cannabis products for both medical and cosmetic applications. Serving international markets, THERAPiN targets both B2C and B2B segments, including pharmaceuticals, cosmetics, and consumers, with a particular emphasis on chronic patients.

Company Intelligence Q&A

What is THERAPiN's primary focus?

THERAPiN's primary focus is on the development, cultivation, and production of raw materials and premium cannabis products for medical and cosmetic use, targeting the international market.

When was THERAPiN founded?

THERAPiN was founded in September 2017.

What is the total funding raised by THERAPiN?

THERAPiN has raised a total of $22 million across 2 funding rounds, with the last funding round being $10 million.

What markets does THERAPiN serve?

THERAPiN serves geomarkets including the United States, Europe, and Israel, catering to both B2C and B2B customers.

What is THERAPiN's current employee count?

THERAPiN currently has 1–10 employees.